Natalizumab discontinuation in the increasing complexity of multiple sclerosis therapy

Neurology. 2014 Apr 29;82(17):1484-5. doi: 10.1212/WNL.0000000000000369. Epub 2014 Mar 28.

Authors

Maria Pia Sormani¹, Nicola De Stefano

Affiliation

¹ From the Department of Health Sciences (M.P.S.), University of Genova; and the Department of Medicine Surgery and Neuroscience (N.D.S.), University of Siena, Italy.

PMID: 24682968
DOI: 10.1212/WNL.0000000000000369

No abstract available

Publication types

Editorial
Comment

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Female
Humans
Immunologic Factors / therapeutic use*
Male
Multiple Sclerosis / drug therapy*
Natalizumab

Substances

Antibodies, Monoclonal, Humanized
Immunologic Factors
Natalizumab